David Ghiyam

Their cognitive decline was dramatically reduced in comparison to control. Published in the New England Journal of Medicine in, I believe, March of this year, was a three-year study giving a GLP-1 agonist drug to patients who already had Parkinson's disease, a disease for which we have no treatment whatsoever.

Their cognitive decline was dramatically reduced in comparison to control. Published in the New England Journal of Medicine in, I believe, March of this year, was a three-year study giving a GLP-1 agonist drug to patients who already had Parkinson's disease, a disease for which we have no treatment whatsoever.

Some of your viewers are going to raise their eyebrows saying, well, I know of drugs that treat Parkinson's, and I, as a neurologist, have treated patients with drugs for 30 years. But they didn't solve something. They just kind of minimized something, right? Exactly. This is symptomatic management. And I'm not derogating it.

Some of your viewers are going to raise their eyebrows saying, well, I know of drugs that treat Parkinson's, and I, as a neurologist, have treated patients with drugs for 30 years. But they didn't solve something. They just kind of minimized something, right? Exactly. This is symptomatic management. And I'm not derogating it.

I mean, there's really a very important benefit to patients to reducing their tremor, to improving their ability to walk and reducing their rigidity. That's for sure.

I mean, there's really a very important benefit to patients to reducing their tremor, to improving their ability to walk and reducing their rigidity. That's for sure.

Any Parkinson's patient or family member right now watching this will recognize that the drugs that their mother or father may be taking are really designed to treat symptoms, which I think is very valuable, but we're treating the smoke, but not the fire. Treat the smoke. That's important. The root cause. Let's look at the fire.

Any Parkinson's patient or family member right now watching this will recognize that the drugs that their mother or father may be taking are really designed to treat symptoms, which I think is very valuable, but we're treating the smoke, but not the fire. Treat the smoke. That's important. The root cause. Let's look at the fire.

There's a 41% increased risk of Parkinson's in diabetics, a metabolic challenge. Oh, man. Because of that, A study was undertaken to determine, well, if we treat Parkinson's patients with a diabetes drug, in this case a GLP-1 agonist drug, how might that affect their time course?

There's a 41% increased risk of Parkinson's in diabetics, a metabolic challenge. Oh, man. Because of that, A study was undertaken to determine, well, if we treat Parkinson's patients with a diabetes drug, in this case a GLP-1 agonist drug, how might that affect their time course?

So Parkinson's patients are rated on a functionality score called the Unified Parkinson's Disease Rating Scale, kind of a common way that we look at Parkinson's patients over time. How quickly are you deteriorating? And we expect over a three-year period to be a moderate decline in functionality.

So Parkinson's patients are rated on a functionality score called the Unified Parkinson's Disease Rating Scale, kind of a common way that we look at Parkinson's patients over time. How quickly are you deteriorating? And we expect over a three-year period to be a moderate decline in functionality.

And in the control group of this study, indeed, there was a decline, a worsening, a higher number on that scale. The patients treated with the GLP-1 ozempic-like drug not only stabilized in terms of that scale, but had a small improvement. Really? Can you imagine? I've never seen that before, but that is finally treating the fire. Wow. That's big. Yeah.

And in the control group of this study, indeed, there was a decline, a worsening, a higher number on that scale. The patients treated with the GLP-1 ozempic-like drug not only stabilized in terms of that scale, but had a small improvement. Really? Can you imagine? I've never seen that before, but that is finally treating the fire. Wow. That's big. Yeah.

Yes. So you as a consumer or the caregiver of that individual should be given information to look at that metric, that risk benefit ratio. What are the downsides and what are the potential upsides? As related to the Parkinson's interventional trial, about 40% of the people receiving the drug had pretty significant gastrointestinal issues.

Yes. So you as a consumer or the caregiver of that individual should be given information to look at that metric, that risk benefit ratio. What are the downsides and what are the potential upsides? As related to the Parkinson's interventional trial, about 40% of the people receiving the drug had pretty significant gastrointestinal issues.

Nausea, vomiting, diarrhea, etc. They lost weight though and they had better memory They had better memory. No, it wasn't even looked at. What they had was they did not decline in terms of their ability to carry out what are called activities of daily living, self-care, mobility, the things that decline in the Parkinson's.

Nausea, vomiting, diarrhea, etc. They lost weight though and they had better memory They had better memory. No, it wasn't even looked at. What they had was they did not decline in terms of their ability to carry out what are called activities of daily living, self-care, mobility, the things that decline in the Parkinson's.

I just finished making a slide. It actually improved a tiny bit. Wow.

I just finished making a slide. It actually improved a tiny bit. Wow.